Longeveron Inc. (LGVN)

$ 18
-2.43 (-11.89%)

Dr. Joshua Michael Hare
Nasdaq Global Select

Longeveron LLC, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was founded in 2014 and is headquartered in Miami, Florida.